期刊文献+

1型糖尿病患者对氧磷酶1活性和氧化低密度脂蛋白水平变化 被引量:5

Changes of serum paraoxonase 1 activity and oxidative low-density lipoprotein level in patients with type 1 diabetes mellitus
原文传递
导出
摘要 目的观察1型糖尿病(type 1diabetes mellitus,T1DM)患者血清对氧磷酶1(paraoxonase 1,PON1)活性和氧化低密度脂蛋白(oxidative low-density lipoprotein,ox-LDL)水平的变化。方法 51例T1DM患者(T1DM组)分为有并发症组36例和无并发症组15例,45例体检健康者对照组,测定各组血清PON1活性、ox-LDL及血生化水平,并分析其相关性。结果 T1DM组血清PON1活性低于对照组(P<0.01),ox-LDL水平高于对照组(P<0.01);有并发症组血清PON1活性低于无并发症组(P<0.01),ox-LDL和三酰甘油水平高于无并发症组(P<0.05);血清PON1活性和ox-LDL水平呈负相关(r=-0.3660,P<0.01)。结论血清PON1活性和ox-LDL水平变化对阐述T1DM的发病机制,预防T1DM并发症的发生有重要意义。 Objective To evaluate paraoxonase 1 (PON1) activity and oxidative low-density lipoprotein (ox-LDL) level in patients with type 1 diabetes mellitus (TIDM). Methods Fifty-one patients with TIDM (36 cases with complications and 15 cases without complications) and forty-five healthy controls were detected serum PON1 activity and ox -LDL level, and analyzed their correlation. Results Serum PON1 activity was lower and ox-LDL level was higher in patients with TIDM than that in healthy controls (P〈0.01). PON1 activity was lower in TIDM patients with complications than that in TIDM patients without complications, and ox-LDL and triacylglycerol levels were higher in T1DM patients with complication than those in patients without complications (P〈0.05). Serum PON1 activity was negatively correlated with ox-LDL level (r=-0. 3660, P〈0.01). Conclusion Evaluation of PON1 activity and ox-LDL level plays an important role in the research of the mechanism of T1DM and the prevention of T1DM complications.
机构地区 解放军第
出处 《中华实用诊断与治疗杂志》 2013年第1期14-15,共2页 Journal of Chinese Practical Diagnosis and Therapy
基金 辽宁省科学技术计划(2011225021)
关键词 1型糖尿病 对氧磷酶1 氧化低密度脂蛋白 Type 1 diabetes mellitus paraoxonase 1 oxidative low density lipoprotein
  • 相关文献

参考文献10

  • 1胡晓莉,孙侃.氧化应激与糖尿病神经病变相关性研究[J].中华实用诊断与治疗杂志,2011,25(4):318-320. 被引量:28
  • 2徐德华,刘文黎,郝丽.糖尿病视网膜病变相关因素分析[J].中华实用诊断与治疗杂志,2009,23(4):412-414. 被引量:13
  • 3黄凯,李燕.对氧磷酶与慢性肝损伤[J].国际药学研究杂志,2011,38(2):112-117. 被引量:5
  • 4Kilpatrick E S, Rigby A S, Atkin S L. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial[J]. Diabetes Care, 2007,30(3): 707 -712.
  • 5Forlenza G P, Rewers M. The epidemic of type 1 diabetes: what is it telling us[J]. Curr Opin Endocrinol Diabetes Obes,2011,18 (4) :248-251.
  • 6Naitoh R, Seino Y. Oxidative stress and development of type 1 diabetes[J]. Nihon Rinsho,2002,60(Suppl 7) :395-398.
  • 7Gupta S, Sharma T K, Kaushik G G, et al. Vitamin E supplementation may ameliorate oxidative stress in type 1 diabetes mellitus patients[J]. Clin Lab,2011,57(5/6):379-386.
  • 8Kotur-Stevuljevic J, Spasic S, Jelic Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients[J]. Clin Biochem,2008,41(13) 1067 -1073.
  • 9李全忠,冯素萍,文世林,傅晓英,张菱,鲁平,周焰,夏威,阚全娥.1型糖尿病并肾病患者眼底及电生理的改变[J].实用诊断与治疗杂志,2004,18(3):174-175. 被引量:8
  • 10Kao Y L, Donaghue K, Chan A, et al. A variant of paraoxonase ( PON1 ) gene is associated with diabetic retinopathyin IDDM[J]. J Clin Endocrinol Metab, 1998,83 (7): 2589-2592.

二级参考文献49

共引文献50

同被引文献68

  • 1Mackness M, Mackness B. Targeting paraoxonase-1 in atherosclerosis[J]. Expert Opin Ther Targets, 201a, 17(7): 829-837.
  • 2Patra SK, Singh K, Singh R. Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus[J]. Diabetes Metab Syndr, 2013, 7(2) : 108-111.
  • 3Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948 59.
  • 4Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes [J]. Lancet, 2014,383(9933) :2008-2017.
  • 5Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008[J:. Am J Med, 2009, 122 (1 Suppl) : 38-50.
  • 6Mancia G, Fagard R, Narkiewiez K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension[J]. Blood Press, 2014,23(1) :3-16.
  • 7Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction:a mendelian randomisation study[J]. Lancet, 2012,380(9841) : 572-580.
  • 8Rajkovic MG, Rumora L, Barisie K. The paraoxonase 1, 2 and 3 in humans[J]. Biochem Med (Zagreb), 2011. 21(2) : 122-130.
  • 9Pcrla-Kaj:n J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism [J]. Amino Acids, 2012, 43 (4) : 1405-1417.
  • 10Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype[J]. Arterioscler Thromb Vasc Biol, 2001,21 (9) : 1451-1457.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部